One Lever, Many Diseases: The Regenerative Brain Protocol

A ketogenic diet is one metabolic fix that reaches many brain diseases. It has been standard care for drug-resistant epilepsy for a century. In Alzheimer’s trials it moved thinking in the right direction, modestly but consistently. APOE4 raises Alzheimer’s risk, but it only loads the gun. Your metabolic terrain decides whether the trigger is pulled.

Over four chapters, the Starved Brain series built one picture. It showed mental decline as a terrain problem: a brain starved of fuel, blocked from building materials, short on nutrients, and poisoned by inflammation. Suppose that is true, and these are four faces of one metabolic failure, not four separate diseases. Then something should follow: one correction should help across many different diagnoses. This finale, Part 5 from Dr. Gurpreet Singh Padda, MD, MBA, MHP, at Regen.MD, closes the loop from mechanism to medicine. It states plainly where the evidence is strong and where it is not.

Does a ketogenic diet help epilepsy?

Before anyone argued about keto on the internet, there was a hospital treatment. For over a hundred years we have known that a ketogenic diet controls seizures. Before good seizure drugs existed, it was the main therapy for epilepsy, and it worked. It never went away. Today, at the top neurology centers in the world, including Johns Hopkins, ketogenic diet therapy is still a standard of care for drug-resistant epilepsy. Randomized trials show more than fifty percent fewer seizures in about half of patients. These are people whom medicines had already failed.

Think about that. A diet change is first-line, proven neurology for one brain disease, and has been for a century. So the idea that changing the brain’s fuel can change brain disease is not a guess. It is established medicine. The only question is how far it reaches.

Does a keto diet help Alzheimer’s?

Go back to where the series started: the Alzheimer’s brain that cannot burn glucose but can still burn ketones. The obvious test writes itself. Give it ketones. When researchers do exactly that, the brain responds. In a randomized controlled trial, a ketogenic drink improved thinking over six months in people with mild cognitive impairment. That is the earliest, most reversible stage. A review that pooled ten randomized trials, covering 691 patients, found ketogenic treatments improved thinking in Alzheimer’s disease. And a randomized crossover trial of a modified ketogenic diet in Alzheimer’s showed gains in daily function and quality of life.

Here is the truth, and it is the whole reason to trust this over the hype. These effects are real but modest. The trials are mostly small and short. This is not a cure, and this series will never call it one. What it is: the first kind of treatment in the whole Alzheimer’s field to consistently move thinking in the right direction by going after the cause. That cause is the brain’s energy crisis, not a single protein. That is truly significant. It is a start worth acting on, not a finish line to oversell.

Can a ketogenic diet help Parkinson’s and other brain diseases?

Now watch the lever move across the map of neurology.

Parkinson’s disease. In a randomized controlled trial, a ketogenic diet improved both movement and non-movement symptoms. It improved the non-movement symptoms (mood, thinking, fatigue) more than a healthy low-fat diet did. And right away, the honesty this series is built on: the broader review of ketogenic therapy in Parkinson’s is truly mixed. A review of the human trials found the evidence scattered and uneven. It could not firmly conclude benefit for many outcomes, even while the animal studies looked promising. The signal is real and worth pursuing under supervision. It is not yet settled. Both things are true.

Multiple sclerosis. This is an area of active, exciting clinical work. It includes case reports of patients with better symptoms and, in some cases, changes on scans. But much of the most dramatic MS work is not yet peer-reviewed. Promising, not proven. Treat anyone claiming otherwise with caution.

Huntington’s disease, a devastating genetic disorder, has a published case report of a time-restricted ketogenic diet. It produced striking gains in movement and function in one patient. One patient is a signal, not proof. But it is a signal in a disease with almost nothing else.

Here is the pattern to see. These are not different magic diets for different diseases. This is one correction of the same upstream metabolic failure, applied to different weak circuits: epilepsy, Alzheimer’s, Parkinson’s, and beyond. Supply the brain’s true fuel and building blocks, and remove what starves and inflames it. That is the whole series in one sentence.

What does APOE4 mean for your Alzheimer’s risk?

Here is the objection heard in the office every week: “This runs in my family. Isn’t it just my genes?” There is a gene variant, APOE4, that is the strongest common genetic risk factor for Alzheimer’s disease. If you carry it, your risk is higher. That is real. But watch what happens when you change the terrain around those genes.

In a 2026 population study, APOE4 carriers who ate the most meat (the top fifth, over 800 grams a week) did not show the higher dementia risk their genes would predict. At high meat intake, the expected genetic handicap basically disappeared in that analysis. And once more, the honesty: this is a single observational study. The strongest signal was in the mental-decline measure. The dementia-risk number itself was borderline. It does not prove that meat overrides APOE4. But it fits everything else in this series like a key in a lock. And it points at the most important idea here: your genes may load the gun; your terrain decides whether the trigger is pulled. If dementia runs in your family, that is not a sentence. It is the strongest possible reason to fix your terrain now, while you still have the reserve to regenerate.

The Regen.MD brain protocol

So what does fixing the terrain look like, done properly by a physician and not off a screen? At Regen.MD, a brain-terrain evaluation is built on the four pillars of this series:

• Fuel. We measure your metabolic and fuel status: glucose, insulin, insulin resistance, and ketone capacity. That shows whether your brain is in the energy crisis described here. It also shows how to move it toward ketone fuel safely, accounting for every medicine you take.
• Structure. We review your lipids through the right lens: whether you have enough of the materials the brain is built from. We also do a careful, doctor-to-doctor review of any medicines that may be crossing into the brain, including fat-soluble statins. Never a one-sided change.
• Nutrients. We test the canary and the flock. That means B12 and its functional markers, homocysteine, vitamin D, and the full brain-nutrient panel, measured against optimal, not merely “normal.”
• Inflammation. We assess the fire: metabolic inflammation, sugar damage to proteins (glycation), and fatty-acid balance. We treat the mouth as part of the brain’s terrain.

Then we build one personal correction across all four, because they are one problem. This is regenerative medicine applied to the brain. Not a symptom chased, but a terrain repaired, so the organ can recover as far as its reserve allows. And the most important thing to know: this works best early. The more brain reserve you still have, the more there is to protect and regenerate. Waiting for a diagnosis is waiting too long.

For more information, get our free guide to knee pain and treatment options.

Frequently asked questions

Key takeaways

• Ketogenic therapy is a century-old standard of care for drug-resistant epilepsy. That proves changing the brain’s fuel can change brain disease.
• In Alzheimer’s, ketogenic treatments show real but modest gains in thinking across randomized trials. Other conditions range from mixed to early, and the series says which is which.
• APOE4 raises Alzheimer’s risk but is not destiny. A single 2026 study suggests terrain (high meat intake) may blunt the genetic risk. That is suggestive, not proof.
• The Regen.MD protocol fixes all four pillars together, under medical supervision, and works best when started early.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary; no outcome is guaranteed. Ketogenic and other significant dietary interventions require medical supervision in the presence of chronic disease and can be dangerous without adjustment of medications for diabetes and blood pressure. Do not start, stop, or change any medication or diet without a qualified physician. To build a supervised, personalized plan, apply for a Clinical Evaluation at Regen.MD or call (314) 295-3000 / text (314) 886-5902.

References

1. Wheless JW. History of the ketogenic diet. Epilepsia. 2008;49(Suppl 8):3-5.
2. Haridas B, Testino A, Kossoff EH. Ketogenic diet therapy for the treatment of pediatric epilepsy. Epileptic Disord. 2025;27(2):144-155.
3. Fortier M, Castellano CA, St-Pierre V, et al. A ketogenic drink improves cognition in mild cognitive impairment: results of a 6-month RCT. Alzheimers Dement. 2021;17(3):543-552.
4. Rong L, Peng Y, Shen Q, Chen K, Fang B, Li W. Effects of ketogenic diet on cognitive function of patients with Alzheimer’s disease: a systematic review and meta-analysis. J Nutr Health Aging. 2024;28(8):100306.
5. Phillips MCL, Deprez LM, Mortimer GMN, et al. Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease. Alzheimers Res Ther. 2021;13(1):51.
6. Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, Lynch CDP. Low-fat versus ketogenic diet in Parkinson’s disease: a pilot randomized controlled trial. Mov Disord. 2018;33(8):1306-1314.
7. Grammatikopoulou MG, Tousinas G, Balodimou C, et al. Ketogenic therapy for Parkinson’s disease: a systematic review and synthesis without meta-analysis of animal and human trials. Maturitas. 2022;163:46-61.
8. Phillips MCL, McManus EJ, Brinkhuis M, Romero-Ferrando B. Time-restricted ketogenic diet in Huntington’s disease: a case study. Front Behav Neurosci. 2022;16:931636.
9. Norgren J, Carballo-Casla A, Grande G, et al. Meat consumption and cognitive health by APOE genotype. JAMA Netw Open. 2026;9(3):e266489.